ADMA Biologics, Inc. (ADMA) stock
ADMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3028% below fair value
$13.63+0.16 (+1.19%)
Close on Nov 17, 2026Market cap $3.05BP/E 19.5Yield –
ADMA Biologics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
ADMA Biologics's operating income for the twelve months ending Jun 30, 2026 was $224.48M, up 44.2% year over year. For fiscal 2025 it was $191.44M, up 37.7% from the year before. The highest annual figure on record is $191.44M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $191.44M | +37.7% |
| FY2024 | Dec 31, 2024 | $138.98M | +542.5% |
| FY2023 | Dec 31, 2023 | $21.63M | – |
| FY2022 | Dec 31, 2022 | -$39.37M | – |
| FY2021 | Dec 31, 2021 | -$58.37M | – |
| FY2020 | Dec 31, 2020 | -$64.91M | – |
| FY2019 | Dec 31, 2019 | -$41.42M | – |
| FY2018 | Dec 31, 2018 | -$60.29M | – |
| FY2017 | Dec 31, 2017 | -$39.31M | – |
| FY2016 | Dec 31, 2016 | -$17.33M | – |
| FY2015 | Dec 31, 2015 | -$15.51M | – |
| FY2014 | Dec 31, 2014 | -$16.02M | – |
| FY2013 | Dec 31, 2013 | -$15.04M | – |
| FY2012 | Dec 31, 2012 | -$7.91M | – |
| FY2011 | Dec 31, 2011 | -$4.62M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $52.45M | +22.5% |
| Q1 FY2026 | Mar 31, 2026 | $58.27M | +67.1% |
| Q4 FY2025 | Dec 31, 2025 | $62.75M | +63.7% |
| Q3 FY2025 | Sep 30, 2025 | $51.01M | +28.7% |
| Q2 FY2025 | Jun 30, 2025 | $42.80M | +9.2% |
| Q1 FY2025 | Mar 31, 2025 | $34.88M | +59.9% |
| Q4 FY2024 | Dec 31, 2024 | $38.32M | +169.3% |
| Q3 FY2024 | Sep 30, 2024 | $39.64M | +356.4% |
| Q2 FY2024 | Jun 30, 2024 | $39.20M | – |
| Q1 FY2024 | Mar 31, 2024 | $21.82M | – |
| Q4 FY2023 | Dec 31, 2023 | $14.23M | – |
| Q3 FY2023 | Sep 30, 2023 | $8.69M | – |
| Q2 FY2023 | Jun 30, 2023 | -$473.00K | – |
| Q1 FY2023 | Mar 31, 2023 | -$813.00K | – |
| Q4 FY2022 | Dec 31, 2022 | -$6.06M | – |
| Q3 FY2022 | Sep 30, 2022 | -$9.32M | – |
| Q2 FY2022 | Jun 30, 2022 | -$9.17M | – |
| Q1 FY2022 | Mar 31, 2022 | -$14.82M | – |
| Q4 FY2021 | Dec 31, 2021 | -$13.19M | – |
| Q3 FY2021 | Sep 30, 2021 | -$14.44M | – |
| Q2 FY2021 | Jun 30, 2021 | -$15.58M | – |
| Q1 FY2021 | Mar 31, 2021 | -$15.16M | – |
| Q4 FY2020 | Dec 31, 2020 | -$17.22M | – |
| Q3 FY2020 | Sep 30, 2020 | -$13.80M | – |
| Q2 FY2020 | Jun 30, 2020 | -$17.12M | – |
| Q1 FY2020 | Mar 31, 2020 | -$16.77M | – |
| Q4 FY2019 | Dec 31, 2019 | -$7.83M | – |
| Q3 FY2019 | Sep 30, 2019 | -$9.05M | – |
| Q2 FY2019 | Jun 30, 2019 | -$11.34M | – |
| Q1 FY2019 | Mar 31, 2019 | -$13.21M | – |
| Q4 FY2018 | Dec 31, 2018 | -$16.55M | – |
| Q3 FY2018 | Sep 30, 2018 | -$13.79M | – |
| Q2 FY2018 | Jun 30, 2018 | -$13.42M | – |
| Q1 FY2018 | Mar 31, 2018 | -$16.53M | – |
| Q4 FY2017 | Dec 31, 2017 | -$10.54M | – |
| Q3 FY2017 | Sep 30, 2017 | -$14.43M | – |
| Q2 FY2017 | Jun 30, 2017 | -$8.40M | – |
| Q1 FY2017 | Mar 31, 2017 | -$5.94M | – |
| Q4 FY2016 | Dec 31, 2016 | -$3.94M | – |
| Q3 FY2016 | Sep 30, 2016 | -$3.74M | – |
See a number that looks wrong?